Hologic completed the acquisition of BioTheranostics from MVM Partners, Evidity Health Care and HealthQuest Capital for £169m.

Hologic, a medical technology company, completed the acquisition of BioTheranostics, a company that improves the care of cancer patients, offering a suite of proprietary genomics-based molecular diagnostics that allow treatment to be tailored to individual patients, from MVM Partners, a venture capital firm, Evidity Health Care, a company that specializes in medical devices, and HealthQuest Capital, a sector-specialist manager that provides growth capital to transformative companies, for £169m. “Acquiring Biotheranostics leverages our strengths in molecular diagnostics and complements our leadership in breast health, while providing attractive growth and return on invested capital,” Steve MacMillan, Hologic Chairman, President and CEO.